New Classifications of Five Distinct “Sleep” Profi... ...
Science in the Age of AI | AI for Science Forum...
Ask the Heart Doctor | Heart Valve Disease and Sur...
High-speed imaging tracks live brain cell activity...
NAD⁺ restores memory in Alzheimer's disease models...
Mark Cuban: A Master Disrupter for American Health...
Teen girls facing the most adversity showed the biggest gain...
September 15,2026
Specialized imaging reveals hormone-driven brain changes...
September 14,2026
Submillimeter MRI reveals brain hubs that guide risky decisi...
September 12,2026
Risk of herpes zoster among breast cancer survivors in Japan...
September 11,2026
Three proteins help organs tailor shared circadian clock to ...
September 10,2026
Should you worry about melatonin and heart failure? The evid...
December 02,2025
Category
Traditional Medicine
Q & A
Wellness
Drug Discovery
Technology & AI
Clinical Pearl Series
Breakthroughs
Immunology & Rheumatology
Reproduction
Hepatobiliary&Pancreas Surgery
Most Read
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Today's News
GOSH BRC Showcase 2025 - Genomic medicine...
Can a twice-a-year shot help end the HIV...
Announcement of the 2025 Nobel Prize in ...
Reprogramming Stem Cells Could Cure Type...
Why MDMA did NOT get FDA approval...
More News
Perioperative Durvalumab Plus Chemo Yields Responses, EFS Benefit in Resectable NSCLC

Perioperative Durvalumab Plus Chemo Yields Responses, EFS Benefit in Resectable NSCLC

September 11, 2023Kyle DohertyThe addition of perioperative durvalumab to neoadjuvant chemotherapy led to a significant improvement in terms of pathological complete response and event-free survival c
Oncology October 11,2023
Perioperative Durvalumab Plus Chemo Yields Responses, EFS Benefit in Resectable NSCLC

Perioperative Durvalumab Plus Chemo Yields Responses, EFS Benefit in Resectable NSCLC

September 11, 2023Kyle DohertyThe addition of perioperative durvalumab to neoadjuvant chemotherapy led to a significant improvement in terms of pathological complete response and event-free survival c
Oncology October 11,2023
Atezolizumab Plus Bevacizumab and Chemotherapy Fails to Provide PFS Benefit in Platinum-Sensitive

Atezolizumab Plus Bevacizumab and Chemotherapy Fails to Provide PFS Benefit in Platinum-Sensitive

September 13, 2023Kyle DohertyThe addition of the PD-L1 inhibitor atezolizumab to bevacizumab and platinum-based chemotherapy did not result in a statistically significant progression-free survival be
Oncology October 11,2023
Atezolizumab Plus Bevacizumab and Chemotherapy Fails to Provide PFS Benefit in Platinum-Sensitive

Atezolizumab Plus Bevacizumab and Chemotherapy Fails to Provide PFS Benefit in Platinum-Sensitive

September 13, 2023Kyle DohertyThe addition of the PD-L1 inhibitor atezolizumab to bevacizumab and platinum-based chemotherapy did not result in a statistically significant progression-free survival be
Oncology October 11,2023
DNA/RNA Sequencing Aids Subsequent Treatment Selection in HCC/H-CCK Post Atezolizumab/Bevacizumab

DNA/RNA Sequencing Aids Subsequent Treatment Selection in HCC/H-CCK Post Atezolizumab/Bevacizumab

September 15, 2023Caroline SeymourTissue- and blood-based molecular analysis could help match patients with advanced hepatocellular carcinoma or hepatocholangiocarcinoma following disease progression
Oncology October 11,2023
DNA/RNA Sequencing Aids Subsequent Treatment Selection in HCC/H-CCK Post Atezolizumab/Bevacizumab

DNA/RNA Sequencing Aids Subsequent Treatment Selection in HCC/H-CCK Post Atezolizumab/Bevacizumab

September 15, 2023Caroline SeymourTissue- and blood-based molecular analysis could help match patients with advanced hepatocellular carcinoma or hepatocholangiocarcinoma following disease progression
Oncology October 11,2023
Luspatercept Provides Frontline Alternative to ESAs For Lower-Risk MDS and Anemia

Luspatercept Provides Frontline Alternative to ESAs For Lower-Risk MDS and Anemia

September 21, 2023Courtney FlahertyUwe Platzbecker, MD, discusses the efficacy and safety data from the COMMANDS trial that supported the approval, and the next steps planned for luspatercept’s invest
Oncology October 11,2023
Luspatercept Provides Frontline Alternative to ESAs For Lower-Risk MDS and Anemia

Luspatercept Provides Frontline Alternative to ESAs For Lower-Risk MDS and Anemia

September 21, 2023Courtney FlahertyUwe Platzbecker, MD, discusses the efficacy and safety data from the COMMANDS trial that supported the approval, and the next steps planned for luspatercept’s invest
Oncology October 11,2023
EMA Grants PRIME Designation to Iopofosine I-131 for Waldenström Macroglobulinemia

EMA Grants PRIME Designation to Iopofosine I-131 for Waldenström Macroglobulinemia

September 18, 2023Kristi RosaThe European Medicines Agency has granted Priority Medicines designation to iopofosine I-131 for use in patients with Waldenström macroglobulinemia in patients who previou
Oncology October 11,2023
EMA Grants PRIME Designation to Iopofosine I-131 for Waldenström Macroglobulinemia

EMA Grants PRIME Designation to Iopofosine I-131 for Waldenström Macroglobulinemia

September 18, 2023Kristi RosaThe European Medicines Agency has granted Priority Medicines designation to iopofosine I-131 for use in patients with Waldenström macroglobulinemia in patients who previou
Oncology October 11,2023
In Down syndrome cells, genome-wide disruptions mimic a senescence-like state

In Down syndrome cells, genome-wide disruptions mimic a senescence-like state

Extra chromosome alters chromosomal conformation and DNA accessibility in neural progenitor cells; study establishes senescence as a potentially targetable mechanism for future treatment.David Orenste
Genetics October 11,2023
In Down syndrome cells, genome-wide disruptions mimic a senescence-like state

In Down syndrome cells, genome-wide disruptions mimic a senescence-like state

Extra chromosome alters chromosomal conformation and DNA accessibility in neural progenitor cells; study establishes senescence as a potentially targetable mechanism for future treatment.David Orenste
Genetics October 11,2023
Study links certain metabolites to stem cell function in the intestine

Study links certain metabolites to stem cell function in the intestine

Molecules called ketone bodies may improve stem cells’ ability to regenerate new intestinal tissue.Anne Trafton|MIT News OfficePublication Date:August 22, 2019 PRESS INQUIRIESMIT bio
Stem cells October 11,2023
Study links certain metabolites to stem cell function in the intestine

Study links certain metabolites to stem cell function in the intestine

Molecules called ketone bodies may improve stem cells’ ability to regenerate new intestinal tissue.Anne Trafton|MIT News OfficePublication Date:August 22, 2019 PRESS INQUIRIESMIT bio
Stem cells October 11,2023
Exploring the links between diet and cancer

Exploring the links between diet and cancer

Omer Yilmaz’s work on how diet influences intestinal stem cells could lead to new ways to treat or prevent gastrointestinal cancers.Anne Trafton|MIT News OfficePublication Date:May 25, 202
Oncology October 11,2023
Exploring the links between diet and cancer

Exploring the links between diet and cancer

Omer Yilmaz’s work on how diet influences intestinal stem cells could lead to new ways to treat or prevent gastrointestinal cancers.Anne Trafton|MIT News OfficePublication Date:May 25, 202
Oncology October 11,2023
Biologists identify key step in lung cancer evolution

Biologists identify key step in lung cancer evolution

Blocking the transition to a more aggressive state could offer a new treatment strategy.Anne Trafton|MIT News OfficePublication Date:May 10, 2017 PRESS INQUIRIESCaption:MIT researche
Oncology October 11,2023
Biologists identify key step in lung cancer evolution

Biologists identify key step in lung cancer evolution

Blocking the transition to a more aggressive state could offer a new treatment strategy.Anne Trafton|MIT News OfficePublication Date:May 10, 2017 PRESS INQUIRIESCaption:MIT researche
Oncology October 11,2023
Human kidneys have been partially grown in pigs for the first time

Human kidneys have been partially grown in pigs for the first time

Early kidney structures made of mostly human cells have been grown in pig embryos for up to 28 days as part of efforts to grow human organs in other animals for transplantsByAlice Klein7 Septemb
Nephrology & Urology October 11,2023
Human kidneys have been partially grown in pigs for the first time

Human kidneys have been partially grown in pigs for the first time

Early kidney structures made of mostly human cells have been grown in pig embryos for up to 28 days as part of efforts to grow human organs in other animals for transplantsByAlice Klein7 Septemb
Nephrology & Urology October 11,2023
More News
Week’s Top
Podcasts
... Health spending has been rising across rich countries with different systems ... ... GOSH BRC Showcase 2025 - Genomic medicine ... ... At what age do people experience depression for the first time? Depression can affect people over long periods of their lives. Some people experience this condition continuously, while for others, it occu...
FIND US ON
ABOUT
Who We Are
Contact Us
Editorial Team
Sitemap
Policy
Privacy Policy
Advertising Policy
Editorial Policy
Corrections Policy
Medical Disclaimer
Alliance
wmo.com
sleep.net
pharm.net
doctors.net
worldsleep.com